Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
8.5
Expiration
Dec 31, 2026
DTE
48d
Moneyness
ITM
Intrinsic
$2.49
IBRX 8.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.83 | +50.91% | 332 | 52 |
| Nov 20, 2026 | 7d | $1.10 | +2.80% | 1 | 150 |
| Nov 27, 2026 | 14d | $1.26 | +16.67% | 6 | 342 |
| Dec 4, 2026 | 21d | $1.30 | +30.00% | 11 | 22 |
| Dec 11, 2026 | 28d | $1.46 | +17.74% | 1 | 6 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.